Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Estramustine
Drug: Etoposide
Drug: Paclitaxel

First Posted Date: 2005-09-08

Last Posted Date: 2015-01-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 28

Registration Number: NCT00151060

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer, Ann Arbor, Michigan, United States

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

Phase 2

Completed

Conditions: Urologic Neoplasms

Interventions: Drug: Trastuzumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2005-09-08

Last Posted Date: 2015-01-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 33

Registration Number: NCT00151034

Locations: 🇺🇸
California City of Hope National Medical Group, Duarte, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
U.C. Davis Medical Center, Sacramento, California, United States

and more 8 locations

A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Docetaxel
Drug: Capecitabine

First Posted Date: 2005-09-07

Last Posted Date: 2014-04-17

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT00148122

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: Cetuximab

First Posted Date: 2005-09-07

Last Posted Date: 2013-01-24

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 36

Registration Number: NCT00148109

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2012-10-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 45

Registration Number: NCT00148070

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Phase 2

Terminated

Conditions: Carcinoma of Unknown Primary

First Posted Date: 2005-09-07

Last Posted Date: 2008-01-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT00148135

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Phase 2

Completed

Conditions: Myeloma, Plasma-Cell
Lymphoma, Malignant
Myeloproliferative Disorders
Myelodysplastic Syndromes
Waldenstrom's Macroglobulinemia

First Posted Date: 2005-09-05

Last Posted Date: 2012-08-09

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 60

Registration Number: NCT00146055

Locations: 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: HER-2 Positive Metastatic Breast Cancer

First Posted Date: 2005-09-05

Last Posted Date: 2012-10-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 22

Registration Number: NCT00146042

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Companion Pharmacogenetic Study to UMCC 9900/9901

Terminated

Conditions: Metastatic Breast Cancer

First Posted Date: 2005-09-05

Last Posted Date: 2008-03-26

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT00146029

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin's

First Posted Date: 2005-09-02

Last Posted Date: 2012-02-01

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 35

Registration Number: NCT00143871

Locations: 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy